Distribution and factors associated with salivary secretory leukocyte protease inhibitor concentrations

Imagem de Miniatura
Arquivos
art_RAHMAN_Distribution_and_factors_associated_with_salivary_secretory_leukocyte_2016.PDF (146.51 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
RAHMAN, S.
CAMPBELL, C. M. Pierce
TORRES, B. N.
O'KEEFE, M. T.
INGLES, D. J.
SILVA, R. J. Carvalho da
CINTRA, R. C.
LAZCANO-PONCE, E.
SALMERON, J.
Citação
ORAL DISEASES, v.22, n.8, p.781-790, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesThis cross-sectional study examined the distribution and correlates of salivary secretory leukocyte protease inhibitor (SLPI) concentrations within a multinational cohort of men. MethodsExtracellular SLPI was measured in oral gargle cell supernatants of 378 men from three countries using an ELISA-based assay. Risk factor data were collected by a questionnaire. Factors associated with SLPI were assessed using linear and logistic regression for continuous and categorical SLPI, respectively. ResultsAmong men aged 18-73years, the median SLPI concentration was 492.0ngml(-1) (range: 2.3-1919.9). In multivariable modeling, men in Brazil and younger men (18-30years) were more likely to have higher levels of SLPI [adjusted odds ratio (aOR) 3.84; 95% confidence interval (CI): 1.94-7.59, and aOR 3.84; 95% CI: 1.98-7.43, respectively]. Men with a self-reported sexually transmitted diseases diagnosis in the past 6months were more likely to have higher SLPI levels (aOR 2.98; 95% CI: 1.1-7.83) and men reporting bleeding/swollen gums were less likely to have higher SLPI (aOR 0.34; 95% CI: 0.15-0.79). Similar results were observed for linear regression models. ConclusionsSecretory leukocyte protease inhibitor concentrations varied significantly by country and decreased with increasing age. The interaction between SLPI, modifiable factors, and oral infections that influence cancer risk warrants further investigation.
Palavras-chave
secretory leukocyte protease inhibitor, immune system protein, saliva, HIM Study
URI
https://observatorio.fm.usp.br/handle/OPI/17052
Referências
  1. Abraham LA, 2000, BONE, V26, P7, DOI 10.1016/S8756-3282(99)00237-9
  2. Adapala VJ, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-5
  3. Bouloukaki I, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-35
  4. Campbell CMP, 2013, J IMMUNOL METHODS, V400, P117, DOI 10.1016/j.jim.2013.10.005
  5. Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
  6. Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596
  7. Cordes C, 2011, INT J ONCOL, V39, P185, DOI 10.3892/ijo.2011.1006
  8. Doumas S, 2005, INFECT IMMUN, V73, P1271, DOI 10.1128/IAI.73.3.1271-1274.2005
  9. Draper DL, 2000, AM J OBSTET GYNECOL, V183, P1243, DOI 10.1067/mob.2000.107383
  10. Ear T, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-14
  11. Alves VTE, 2013, INFECT IMMUN, V81, P4399, DOI 10.1128/IAI.01107-13
  12. Fakioglu E, 2008, J VIROL, V82, P9337, DOI 10.1128/JVI.00603-08
  13. Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
  14. Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995
  15. Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
  16. Guggenheimer J, 2003, J AM DENT ASSOC, V134, P61
  17. Hoffmann M, 2013, ONCOL REP, V29, P1962, DOI 10.3892/or.2013.2327
  18. Jana NK, 2005, J VIROL, V79, P6432, DOI 10.1128/JVI.79.10.6432-6440.2005
  19. Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2
  20. Kreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682
  21. Larbi A, 2013, AGING HLTH, V9, P35
  22. Laugisch O, 2012, MOL ORAL MICROBIOL, V27, P45, DOI 10.1111/j.2041-1014.2011.00631.x
  23. Lee J, 2012, J DENT RES, V91, P142, DOI 10.1177/0022034511421200
  24. Lee SE, 2010, YONSEI MED J, V51, P808, DOI 10.3349/ymj.2010.51.6.808
  25. Lin AL, 2004, J ORAL PATHOL MED, V33, P410, DOI 10.1111/j.1600-0714.2004.00218.x
  26. Lourbakos A, 1998, FEBS LETT, V435, P45, DOI 10.1016/S0014-5793(98)01036-9
  27. Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001
  28. Ma G, 2004, J EXP MED, V200, P1337, DOI 10.1084/jem.20041115
  29. Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25
  30. Mehanna H, 2013, HEAD NECK-J SCI SPEC, V35, P747, DOI 10.1002/hed.22015
  31. Meyer M, 2014, AM J PHYSIOL-LUNG C, V306, pL269, DOI 10.1152/ajplung.00290.2013
  32. Moreau T, 2008, BIOCHIMIE, V90, P284, DOI 10.1016/j.biochi.2007.09.007
  33. Mortazavi H, 2014, Ann Med Health Sci Res, V4, P503, DOI 10.4103/2141-9248.139284
  34. Nagler RM, 2004, BIOGERONTOLOGY, V5, P223, DOI 10.1023/B:BGEN.0000038023.36727.50
  35. Nicol AF, 2016, JAIDS-J ACQ IMM DEF, V73, P27, DOI 10.1097/QAI.0000000000001049
  36. Nystrom M, 1999, MEDIAT INFLAMM, V8, P147, DOI 10.1080/09629359990478
  37. Odaka C, 2003, J IMMUNOL, V171, P1507
  38. PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x
  39. Sallenave JM, 1997, J LEUKOCYTE BIOL, V61, P695
  40. SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733
  41. Ship JA, 2002, J AM GERIATR SOC, V50, P535, DOI 10.1046/j.1532-5415.2002.50123.x
  42. Shugars DC, 2001, GERONTOLOGY, V47, P246, DOI 10.1159/000052808
  43. Skeate JG, 2016, J GEN VIROL, V97, P422, DOI 10.1099/jgv.0.000341
  44. Tse KP, 2012, ANTICANCER RES, V32, P1299
  45. Vroling AB, 2011, MOL IMMUNOL, V48, P630, DOI 10.1016/j.molimm.2010.11.002
  46. Wahl S M, 1997, Oral Dis, V3 Suppl 1, pS64
  47. Wen J, 2011, AM J PATHOL, V178, P2866, DOI 10.1016/j.ajpath.2011.02.017
  48. Woodham AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043519
  49. Young D, 2015, ORAL ONCOL, V51, P727, DOI 10.1016/j.oraloncology.2015.03.015

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03